What's breaking now, across thousands of outlets.
(MedPage Today) -- The FDA approved zanidatamab (Ziihera) plus tislelizumab (Tevimbra) and chemotherapy as first-line treatment for unresectable/metastatic HER2-positive gastroesophageal cancer. The approval stipulates use in adults with unresectable...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
A Missouri mom describes the horrifying moment she found her newborn unresponsive and sprang into action.
The FDA has authorized the first wearable in the U.S. to continuously monitor ketone levels and the first device globally to track both ketones and glucose together in a single system.
Rhabdomyosarcomas are a rare form of cancer; however, the disease is responsible for about 60% of all soft-tissue sarcomas in children.
Standard memory tests, such as word-pair or list-learning tests used in clinics, may fail to detect the real-life memory problems reported by many female breast cancer survivors after chemotherapy.
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
President John Dramani Mahama has called for a more responsive healthcare regulatory system to improve patient safety and protect public trust in healthcare delivery.
